

Safety, immunogenicity and efficacy against febrile malaria of the candidate vaccines FP9 ME-TRAP and MVA ME-TRAP for children in an endemic area

Submission date 13/09/2005	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 14/10/2005	Overall study status Completed	☐ Protocol
Last Edited 05/03/2019	Condition category Infections and Infestations	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Philip Bejon

Contact details

Wellcome Trust Laboratories
Kilifi KEMRI-Wellcome Trust Collaborative Programme
PO Box 80108 - 230
Kilifi
Kenya

-
+254 (0)41 522063/522535/435/044
pbejon@kilifi.kemri-wellcome.org

Additional identifiers

Protocol serial number

073597

Study information

Scientific Title

Safety, immunogenicity and efficacy against febrile malaria of the candidate vaccines FP9 ME-TRAP and MVA ME-TRAP for children in an endemic area: a randomised controlled trial

Study objectives

To compare the following outcome measures in children immunised with a control immunisation (rabies vaccine) or FP9:ME-TRAP MVA:ME-TRAP during two three to four month surveillance periods spanning the malaria transmission seasons:

1. Rates of development of febrile malaria and proportions of children with episodes of febrile malaria
2. The incidence of solicited local side-effects at the site of injection and systemic side-effects in the days following immunisation
3. The immediate effector T cell response and long-term memory T cell response after vaccination

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Kenyan Medical Research Institute National Ethical Review Committee, 23/11/2004, ref: SSC Protocol 915
2. Central Office for Research Ethics Committees (COREC), 09/02/2005, ref: 05/Q1604/9

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Febrile malaria

Interventions

This study will evaluate the efficacy of the regime of FP9:ME-TRAP (attenuated Fowlpox virus recombinant for ME-TRAP) followed by MVA:ME-TRAP (modified Vaccinia Ankara recombinant for ME-TRAP) in one to six year old children in Kilifi District, Kenya, during two three to four month surveillance periods spanning the malaria transmission seasons. The trial will be randomised and double blind, using rabies vaccine as control. We will screen 450 children, aiming to recruit 410 children to be randomised in a 1:1 ratio to active or control vaccinations.

Intervention Type

Biological/Vaccine

Phase

Phase II

Primary outcome(s)

1. Safety and immunogenicity data will be evaluated by clinical assessments and blood tests
2. Subsequent weekly follow up will allow blood film examinations for all febrile children
3. Rates of development of febrile malaria and proportions of children with episodes of febrile malaria will be compared between groups to determine efficacy

Key secondary outcome(s)

No secondary outcome measures

Completion date

01/11/2006

Eligibility

Key inclusion criteria

1. Aged one to six years old, either sex
2. Resident in the study area

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

1 Years

Upper age limit

6 Years

Sex

All

Key exclusion criteria

1. Clinically significant skin disorder, allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness, severe malnutrition (mid-upper arm circumference less than 11 cm)
2. History of splenectomy
3. Serum creatinine concentration above the age related normal range in Kilifi
4. Serum alanine aminotransferase (ALT) concentration above the normal range in Kilifi
5. Clinically significant anaemia (i.e. with symptoms of limited exercise capacity, or signs of a high cardiac output state; large volume pulse, heaving cardiac apex beat, resting tachycardia)
6. Blood transfusion within one month of the beginning of the study
7. History of vaccination with previous experimental malaria vaccines
8. Administration of any other vaccine or immunoglobulin within two weeks before vaccination
9. Current participation in another clinical trial, or within 12 weeks of this study

10. Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial

11. Likelihood of travel away from the study area

Date of first enrolment

01/02/2005

Date of final enrolment

21/03/2005

Locations

Countries of recruitment

Kenya

Study participating centre

Wellcome Trust Laboratories

Kilifi

Kenya

-

Sponsor information

Organisation

University of Oxford (UK)

ROR

<https://ror.org/052gg0110>

Funder(s)

Funder type

University/education

Funder Name

London School of Hygiene and Tropical Medicine (UK)

Funder Name

Wellcome Trust

Alternative Name(s)**Funding Body Type**

Private sector organisation

Funding Body Subtype

International organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	20/10/2006		Yes	No